甲硫氨酸缺乏通过改变免疫检查点转录本的m6A甲基化促进抗肿瘤免疫
该研究在小鼠模型中评估限制甲硫氨酸饮食(MRD)的抗肿瘤免疫效应,并在体外和体内探讨甲硫氨酸及YTHDF1在肿瘤免疫逃逸中的作用。结果显示MRD减少肿瘤生长、增强抗肿瘤免疫,机制涉及甲硫氨酸来源的S-腺苷甲硫氨酸促进免疫检查点PD-L1和VISTA的m6A甲基化与翻译;MRD或YTHDF1缺失与PD-1阻断协同增效。临床上YTHDF1表达与癌症患者不良预后和免疫治疗结局相关。
要点
- 限制甲硫氨酸饮食在小鼠模型中减少肿瘤生长并增强抗肿瘤免疫。
- 甲硫氨酸代谢通过S-腺苷甲硫氨酸促进肿瘤细胞PD-L1和VISTA的m6A甲基化与翻译。
- MRD或YTHDF1缺失与PD-1阻断协同增强肿瘤控制。
核心结论
- 甲硫氨酸和YTHDF1通过调节T细胞功能在抗癌免疫中起关键作用,靶向甲硫氨酸代谢或YTHDF1可能是癌症免疫治疗的新策略。
研究设计与样本
- 在小鼠模型中评估限制甲硫氨酸饮食(MRD)的抗肿瘤免疫效应,并在体外和体内确定甲硫氨酸和含YTH结构域家族蛋白1(YTHDF1)在肿瘤免疫逃逸中的机制。
- 进一步研究MRD或YTHDF1缺失与PD-1阻断的协同效应。
主要发现
- 在不同小鼠模型中,限制饮食甲硫氨酸减少肿瘤生长并通过增加肿瘤浸润CD8+ T细胞的数量和细胞毒性增强抗肿瘤免疫。
- 源自甲硫氨酸代谢的S-腺苷甲硫氨酸促进肿瘤细胞中免疫检查点(包括PD-L1和VISTA)的N6-甲基腺苷(m6A)甲基化和翻译。
- MRD或m6A特异性结合蛋白YTHDF1缺失通过恢复CD8+ T细胞浸润抑制肿瘤生长,并与PD-1阻断协同实现更好的肿瘤控制。
- 临床上,YTHDF1表达与癌症患者的不良预后和免疫治疗结局相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Methionine metabolism is involved in a myriad of cellular functions, including methylation reactions and redox maintenance. Nevertheless, it remains unclear whether methionine metabolism, RNA methylation and antitumour immunity are molecularly intertwined. DESIGN: The antitumour immunity effect of methionine-restricted diet (MRD) feeding was assessed in murine models. The mechanisms of methionine and YTH domain-containing family protein 1 (YTHDF1) in tumour immune escape were determined in vitro and in vivo. The synergistic effects of MRD or YTHDF1 depletion with PD-1 blockade were also investigated. RESULTS: We found that dietary methionine restriction reduced tumour growth and enhanced antitumour immunity by increasing the number and cytotoxicity of tumour-infiltrating CD8+ T cells in different mouse models. Mechanistically, the S-adenosylmethionine derived from methionine metabolism promoted the N6-methyladenosine (m6A) methylation and translation of immune checkpoints, including PD-L1 and V-domain Ig suppressor of T cell activation (VISTA), in tumour cells. Furthermore, MRD or m6A-specific binding protein YTHDF1 depletion inhibited tumour growth by restoring the infiltration of CD8+ T cells, and synergised with PD-1 blockade for better tumour control. Clinically, YTHDF1 expression correlated with poor prognosis and immunotherapy outcomes for cancer patients. CONCLUSIONS: Methionine and YTHDF1 play a critical role in anticancer immunity through regulating the functions of T cells. Targeting methionine metabolism or YTHDF1 could be a potential new strategy for cancer immunotherapy.
引用
- Li T, Tan YT, Chen YX, et al. Methionine deficiency facilitates antitumour immunity by altering m6A methylation of immune checkpoint transcripts. Gut. 2022. PMID: 35803704. doi:10.1136/gutjnl-2022-326928
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。